Research programme: ion channel modulators - Neurion Pharmaceuticals/Eli Lilly and Company
Latest Information Update: 11 Oct 2005
At a glance
- Originator Eli Lilly and Company; Neurion Pharmaceuticals
- Class Small molecules
- Mechanism of Action Ion channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued CNS disorders
Most Recent Events
- 11 Oct 2005 Discontinued - Preclinical for CNS disorders in USA (unspecified route)
- 24 Jul 2003 Preclinical trials in CNS disorders in USA (unspecified route)